louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05409703: The Effect of Reiki on Executive Nurses
Official title: The Effect of Reiki on Executive Nurses on Psychological Empowerment, Happiness, Emotion Management and Work Engagement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Reiki Therapy
Keywords: Executive Nurses
Reiki
Psychological Empowerment
Happiness
Emotion Management
Lead sponsor: Cukurova University
Sponsor class: OTHER
First posted: 2022-06-08
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is a randomized controlled experimental study.
Primary purpose: TREATMENT

Brief summary: In this study, the traditional Usui Reiki protocol was applied for distant healing. Each session; It was applied approximately once a week, for 30 minutes, for two weeks. A certified Reiki practitioner (one of the researchers) received an energy transfer from his home, 80 km away. The practitioner is trained in the reiki line and has been practicing and continuing to practice reiki for over 5 years.

Detailed description: The practitioner made an appointment over the phone to conduct individual sessions during the morning hours when each participant was available. Before the first session, the online pre-assessment tools (Google form) of the study were delivered to the participant, and then a statement of intent was sent to the participant. The person who will take the session is requested to be in a comfortable position. During the application, he/she can talk, sleep, work if he/she wishes. However, he was warned not to use tools and cutting tools. The second session will be held at the same time, one week later, and the online final evaluation forms were asked to be filled one day later. The group will be re-evaluated after 21 days. No intervention was made in the control group. The same measurement tools were used in all groups.

Eligibility criteria: Inclusion Criteria:

Holding a managerial position, Executive nurses who have not received reiki therapy before will be included in the study.

Exclusion Criteria:

Previous or current reiki therapy Reiki practitioner or instructor, Nurses who are not in a managerial position will not be included in the study.

Primary outcomes:
measure: The Effect of Reiki on Executive Nurses on Psychological Empowerment
timeFrame: Scales are filled after 6 weeks of application.
measure: The Effect of Reiki on Executive Nurses on Emotion Management and Work Engagement
timeFrame: Scales are filled after 6 weeks of application.
Secondary outcomes:
Other outcomes:
Locations:
city: Osmaniye
country: Turkey
facility: Zehra Bayram
Study officials:
affiliation: Osmaniye Korkut Ata University
name: Hilal Kuşçu Karatepe, phD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00881803: Iron & Vitamin C Study
Official title: Implications of Concurrent Iron and Ascorbic Acid Supplementation on Iron Status in Persons With Spinal Cord Injury
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Spinal Cord Injury
Keywords: Spinal Cord Injuries
Ascorbic Acid
Vitamin C
Iron
Dietary Supplements
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2009-04-15
Enrollment: 60
Sex: MALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: US Veterans with spinal cord injuries greater than 6 months who are located near Bronx, NY

Brief summary: Iron overload is a life-threatening condition that can lead to liver disease, cardiac disease, diabetes and arthritis. Simultaneous supplementation with both iron and AA may place individuals with SCI at risk for iron overload as well as oxidative damage by iron-generated free radicals. Both conditions of high and low iron stores may present with common signs and symptoms. Accurate diagnosis of iron disorder should consider CRP, hematocrit, hemoglobin, serum iron, TIBC, percent saturation of iron binding capacity, serum ferritin and hepcidin.

The investigators are proposing a study to determine the effect of concurrent AA and iron supplementation on iron status of individuals with SCI. The investigators goal is to identify abnormal status that may be attributed to simultaneous supplementation of iron and AA to develop future supplementation protocols in this population for optimal iron status.


Eligibility criteria: Inclusion Criteria:

1. Male
2. 18 years to 90 years of age
3. Medically stable
4. Chronic SCI (\>6 months post injury) without regard to the level or completeness of lesion
5. Supplementation with:

   * A standard recommended dose of 120-200 mg oral elemental iron (tablet or liquid; ferrous sulfate, fumarate or gluconate forms) for a minimum of 6 months; or
   * A standard recommended dose of 250-2,000 mg AA per day for a minimum of 6 months; or
   * Both 120-200 mg oral elemental iron AND 250-2,000 mg AA per day for a minimum of 6 months.
6. Veteran

Exclusion Criteria:

Acute cardiovascular, pulmonary or renal conditions

Primary outcomes:
measure: To determine iron status if supplemented with ascorbic acid (AA) and/or iron compared to supplementation with iron or AA.
timeFrame: 1 episode, at least 6 months after consistent ascorbic acid and/or iron supplementation
Secondary outcomes:
measure: Determine the prevalence of high iron status if receiving supplementation with both iron and AA compared to supplementation with iron or AA.
timeFrame: 1 episode, at least 6 months after consistent ascorbic acid and/or iron supplementation.
Other outcomes:
Locations:
city: Bronx
country: United States
facility: VA Medical Center, Bronx
state: New York
Study officials:
affiliation: VA Medical Center, Bronx
name: William Bauman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04958603: The Clinical Effect of Different Lateral Retinaculum Relaxation Methods in the Treatment of LPCS
Official title: The Clinical Effect of Different Lateral Retinaculum Relaxation Methods in the Treatment of Lateral Patellar Compression Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lateral Patellar Compression Syndrome
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-12
Enrollment: 64
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: From September 2004 to January 2019, patients with lateral patella overcrowding syndrome treated by deputy chief physician Yang Yuping of the Department of Sports Medicine, Peking University Third Hospital

Brief summary: To observe the comparison of the clinical effects of two different ways of loosening the lateral support band under arthroscopy to treat lateral patella excessive compression syndrome.

Detailed description: To analyze the surgical conditions of 64 patients with lateral patella excessive compression syndrome who were surgically treated by Deputy Chief Physician Yang Yuping of the Department of Sports Medicine, Peking University Third Hospital from September 2004 to January 2019. Among them, 24 early cases used the traditional proximal release of the lateral retinaculum (traditional surgical group), and recently 40 cases, after learning from the surgical experience of the early cases, switched to the lateral release of the lateral retinaculum, that is, "L" type Release (new surgery group). The visual analog scale (VAS), Lysholm score, and IKDC knee function subjective evaluation scale (IKDC) score were performed before and after the operation. By analyzing the knee movement scores of patients before and after surgery, the efficacy of the above two operations was judged, and the two groups of postoperative scores were evaluated.

Eligibility criteria: Inclusion Criteria:

* From September 2004 to January 2019, patients with lateral patella overcrowding syndrome treated by deputy chief physician Yang Yuping of the Department of Sports Medicine, Peking University Third Hospital

Exclusion Criteria:

* From September 2004 to January 2019, patients with lateral patella overcrowding syndrome treated by deputy chief physician Yang Yuping of the Department of Sports Medicine, Peking University Third Hospital

Primary outcomes:
measure: Visual analogue scale (VAS)
timeFrame: Six months after surgery
measure: (International Knee Documentation Committee) IKDC knee function subjective evaluation form score
timeFrame: Six months after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Univerisity Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: yuping yang
role: STUDY_CHAIR
References:
Clinical trial NCT01003743: Endolumenal Gastric Pouch and Gastrojejunal Anastomosis Reduction
Official title: Endolumenal Gastric Pouch and Gastrojejunal Anastomosis Reduction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dilated Gastric Tissue
Lead sponsor: USGI Medical
Sponsor class: INDUSTRY
First posted: 2009-10-29
Sex: ALL
Minimum age (years): 19
Maximum age (years): 64
Standard ages: ADULT

Brief summary: Registry is designed to evaluate use of endolumenal tissue anchors for soft tissue approximation to repair a dilated gastric pouch and gastrojejunal anastomosis in post-Roux-En-Y gastric bypass patients presenting with weight regain. Registry will also assess tissue anchor durability.


Eligibility criteria: Inclusion Criteria:

1. Patient is \> 18 years of age and \< 65 years of age
2. Patient is \> 2 yrs post-Roux-en-Y bypass surgery
3. Patient initially achieved \> 50% EWL after Roux-en-Y bypass surgery
4. Patient is a reasonable risk to undergo general anesthesia
5. Patient is able to provide written informed consent

Exclusion Criteria:

1. Patient has an esophageal stricture or other anatomy/condition that would preclude the use and passage of the endolumenal instruments
2. Physician determines another causal factor for weight regain other than stoma or pouch dilation
3. Patient is non-mobile or has significant impairment of mobility that will limit compliance with post-op exercise

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: University of California, San Diego
state: California
Study officials:
References:
Clinical trial NCT04850443: Treatment of IL-6 and Its Receptor Antagonists in Children's Severe Sepsis.
Official title: Effects of IL-6 and Its Receptor Antagonists in the Treatment of Children With Severe Infection and Inflammatory Storm
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Critical Illness Sepsis, Severe
Keywords: Critical Illness, Sepsis, children, tocilizumab, siltuximab
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
First posted: 2021-04-20
Enrollment: 0
Sex: ALL
Minimum age (years): 29
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All children hospitalized in pediatric intensive care unit (PICU) of Children's Hospital of Fudan University from January 2022 to December 2023

Brief summary: In severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe secondary hospital-acquired infections. However, the role of IL-6 and its receptor antagonists in patients with severe sepsis and septic shock is discussed controversially. To date, the efficacy and safety of IL-6 and its receptor antagonists in children with severe infection is not fully evaluated.

Detailed description: The investigators intend to enroll all children who were hospitalized in pediatric intensive care unit of Children's Hospital of Fudan University from January 2022 to December 2023. Children with a PICU length of day less than 48h will be excluded. Patients who met the inclusion criteria will be divided into trial group and control group. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record.

Eligibility criteria: Inclusion Criteria:

* 1.Children between 29 days and 18 years old. 2.Severe pneumonia and/or sepsis.Patients were included who meet the guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019) issued by the National Health Commission of the people's Republic of China and/or who meet the International Guide to the 2020 campaign to Save sepsis: management of septic shock and sepsis-related organ dysfunction in children.

Exclusion Criteria:

* 1.notifiable infectious diseases. 2.The researcher believes that he is not suitable to participate in other situations in this study. 3.Participants in other clinical trials in the same period. 4. discharge within 48 hours.

Primary outcomes:
measure: survival rate
timeFrame: within 28 days after they discharged from PICU
Secondary outcomes:
measure: length of stay in PICU
timeFrame: up to 28 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03373643: Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease
Official title: Association Between Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease Investigated by Liver Biopsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Non-alcoholic Fatty Liver Disease
Sleep Apnea, Obstructive
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2017-12-14
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: Obstructive sleep apnea (OSA) and nonalcoholic fatty liver disease (NAFLD) are frequently encountered in patients with metabolic syndrome (MS). Several data suggest that OSA per se could be a risk factor of liver injury. Most previous studies evaluating the association between OSA severity and the severity of NAFLD used indirect markers of NAFLD including liver imaging or liver injury blood markers or have been performed in morbidly obese patients undergoing intraoperative needle liver biopsy during bariatric surgery.

The current study propose to investigate with a full night polysomnography consecutive patients undergoing percutaneous liver biopsy for suspected NAFLD.


Eligibility criteria: Inclusion Criteria:

* Suspected NAFLD requiring per-cutaneous liver biopsy

Exclusion Criteria:

* Other than NAFLD liver disease
* Previously diagnosed or treated OSA
* Excessive alcohol consumption (\>220 gr/week for men, \>140 gr/week for women)
* Pregnancy
* Surgical treatment for obesity past history

Primary outcomes:
measure: Association between OSA severity marker (apnea hypopnea index per hour on the polysomnography) and significant liver fibrosis (score F3 and F4 of the histological nonalcoholic steatohepatitis [NASH]-CRN classification)
timeFrame: The polysomnography will be performed no more than 3 months after the liver biopsy.
Secondary outcomes:
measure: Association between OSA severity marker (apnea hypopnea index per hour on the polysomnography) and significant nonalcoholic steatohepatitis (3 positive criteria on NASH-CRN classification)
timeFrame: The polysomnography will be performed no more than 3 months after the liver biopsy.
measure: Association between OSA severity marker (apnea hypopnea index per hour on the polysomnography) and significant liver steatosis (histological steatosis > 33% or stade 2 or more on NASH-CRN)
timeFrame: The polysomnography will be performed no more than 3 months after the liver biopsy.
Other outcomes:
Locations:
city: Angers
country: France
facility: CHU Angers
state: Please Select
Study officials:
References:
Clinical trial NCT06667843: Smart Nutrition, Healthier Communities
Official title: Smart Nutrition, Healthier Communities: a Digital Therapeutic Strategy for Early Obesity Intervention
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Obesity and Overweight
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: Stjørdal Municipally
name: Lifeness AS
name: National patient organization (LFO)
First posted: 2024-10-31
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: RCT
Primary purpose: TREATMENT

Brief summary: The project investigates the effect of the health app Lifeness as a digital therapeutic (DTx) and follow-up tool in a municipal setting at a regional Healthy Lives Center in central Norway (Frisklivssentralen Værnesregionen), targeting early intervention for overweight and obesity.


Eligibility criteria: Inclusion Criteria:

* BMI ≤27kg/m2 or obesity measured by waist circumference, current weight stability, motivated to lifestyle change using mobile apps, access to smartphone with 5G. Living in the municipallies covered by the Værnes region of central Norway.

Exclusion Criteria:

* previous bariatric surgery, use of anti-obesity drugs, pregnancy, current or present cancer diagnosis,substance abuse or psychiatric diagnosis (such as eating disorders), or other conditions that can hinder physical activity.

Primary outcomes:
measure: Body weight
timeFrame: 12 weeks
Secondary outcomes:
measure: Eating behavior and hedonic appetite
timeFrame: 12 weeks
measure: Weight related quality of life
timeFrame: 12 weeks
Other outcomes:
measure: Feasability
timeFrame: 12 weeks
Locations:
city: Stjørdal
country: Norway
facility: Frisklivssentralen Værnesregionen
state: Trøndelag
city: Trondheim
country: Norway
facility: Norwegian University of Science and Technology
state: Trøndelag
Study officials:
References:
Clinical trial NCT03792243: Outcomes After Parastomal Hernia Repair
Official title: Outcomes After Parastomal Hernia Repair
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parastomal Hernia
Lead sponsor: Zealand University Hospital
Sponsor class: OTHER
Collaborators: name: Danish Hernia Database
First posted: 2019-01-03
Enrollment: 1062
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients undergoing parastomal hernia repair in Denmark from 2007-2017

Brief summary: The aim of the current study is to evaluate the overall outcomes after parastomal hernia repairs in Denmark from 2007-2017 using data from the Danish Hernia Database and Danish Patients Registry. Specifically, the readmission and reoperation rates will be evaluated.

Detailed description: The Danish Hernia Database covers about 80% of all ventral hernia repairs performed in Denmark. Data on size of hernia, type of surgery, type of mesh and fixation method is available from the Danish Hernia Database. All healthcare services in Denmark are registered in the Danish National Patients Registry and data on 30-day readmission rate, readmission diagnosis and reoperation is found here. Each Danish citizen has a unique personal identification number and by merging data from the Danish Hernia Database and National Patients Registry, nationwide data on parastomal hernia repairs is available. The aim of the current study is to evaluate the overall outcomes after parastomal hernia repairs in Denmark from 2007-2017 focusing on readmission and reoperation rates.

Eligibility criteria: Inclusion Criteria:

* All patients undergoing parastomal hernia repair in Denmark from 2007-2017

Exclusion Criteria:

* If data is not fully registered in the Danish Hernia Database

Primary outcomes:
measure: Reoperation
timeFrame: 30 days
Secondary outcomes:
measure: Readmission
timeFrame: 90 days
measure: Recurrence
timeFrame: 10 years
Other outcomes:
Locations:
city: Køge
country: Denmark
facility: Dept. of surgery, Køge Hospital
Study officials:
affiliation: Zealand University Hospital, Koege, Dept. of Surgery
name: Nadia Henriksen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06384443: Proton Pump Inhibitors in Cirrhotic Patients
Official title: Inappropriate Use of Proton Pump Inhibitors in Patients With Liver Cirrhosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Proton Pump Inhibitor Adverse Reaction
Liver Cirrhosis
Keywords: Proton pump inhibitors
liver cirrhosis
spontaneous bacterial peritonitis
hepatic encephalopathy
portal hypertension
Lead sponsor: National Liver Institute, Egypt
Sponsor class: OTHER
First posted: 2024-04-25
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with a histological, biochemical, imaging and/or clinical data of cirrhosis

Brief summary: Proton pump inhibitors (PPIs) inappropriate use, in patients with cirrhosis, presents a significant clinical challenge. This study evaluates overprescription and misuse of PPIs in cirrhotic patients. The patterns of use of PPIs will be classified into two groups based on adherence to the proven indications: Group A: Inappropriate use of PPI, Group B: Appropriate use of PPI. We will estimate the prevalence of PPI misuse in cirrhotics and correlate it with different factors.

Detailed description: The inappropriate use of PPIs in cirrhosis patients is a growing concern. Evidence supporting the use of PPIs in cirrhosis-related conditions is limited. Several adverse outcomes have been linked to PPI use in cirrhosis, including an increased risk of spontaneous bacterial peritonitis and hepatic encephalopathy.

The study aimed to assess the appropriateness of prescribing PPIs to patients with cirrhosis, examining its impact on prescribing practices and identifying associated factors.

in this observational, descriptive, cross-sectional study, cirrhotic patients receiving proton pump inhibitors will be included in the study. Enrolled patients will classified according to the indication for PPI administration: Group A: Inappropriate use of PPI, Group B: Appropriate use of PPI. Use of PPI will be considered inappropriate when prescribed without approved indication or used for a prolonged period beyond the recommended duration. The prevalence of PPI misuse in cirrhotics will be estimated and multivariate analyses will be conducted in order to identify independent predictors of inappropriate use of PPI.

Eligibility criteria: Inclusion Criteria:

* Patients receiving proton pump inhibitors at the time of enrollment.

Exclusion Criteria:

* Refusal to sign the informed consent form or failure to provide the required information

Primary outcomes:
measure: Inappropriate use of PPIs
timeFrame: Six weeks after study completion
measure: Predictors for inappropriate use of PPIs
timeFrame: Eight weeks after study completion
Secondary outcomes:
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: National Liver institute - Menoufia University
state: Menoufia
Study officials:
affiliation: National Liver Institute, Menoufia University
name: Gasser I El-Azab, M.D.
role: PRINCIPAL_INVESTIGATOR
References: